Systemic Corticosteroids Resolve Immune-related AEs in Ipilimumab-treated Metastatic Melanoma Patients
Systemic corticosteroids resolve immune-mediated adverse reactions associated with ipilimumab treatment.
American Society of Clinical Oncology (ASCO)
No Superiority Seen Over FOLFOX4 in Resectable Metastatic Colorectal Cancer Compared with FOLFOX7 Followed by FOLFIRI
Dose-dense oxaliplatin therapy followed by an irinotecan-based regimen does not improve outcomes over standard FOLFOX4 chemotherapy for metastatic colorectal cancer patients.
Bevacizumab + Chemo Improves Progression-Free Survival in Platinum-Resistant Ovarian Cancer
In women with platinum-resistant ovarian cancer, bevacizumab plus chemotherapy doubled progression-free survival (PFS) compared with chemotherapy alone.
Adding Aflibercept to FOLFIRI for mCRC Yields Longer Survival Trend
Despite a high incidence of adverse events, adding aflibercept to FOLFIRI chemotherapy is associated with “a consistent trend” of increased survival among metastatic colorectal cancer patients, regardless of patients’ previous bevacizumab treatment status, according to a study presented at the 2012 American Society of Clinical Oncology Annual Meeting.
1p/19q Co-Deletion Key in Anaplastic Oligodendroglioma Chemo
Adding procarbazine, lomustine and vincristine chemotherapy to radiotherapy increases PFS and OS in patients with anaplastic oligodendroglial tumors and represents a new standard of care in those with 1p/19q co-deletions, according to data presented at the 2012 American Society of Clinical Oncology Annual Meeting.
No Survival Benefit with Induction Chemo for Squamous Cell Carcinoma of the Head and Neck
Induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck did not improve OS, according to a study presented at the 2012 American Society of Clinical Oncology Annual Meeting.
No OS Benefits with Addition of Perifosine to Capecitabine in mCRC
Adding perifosine to capecitabine does not prolong overall survival in refractory metastatic colorectal cancer, according to results of phase 3 study reported at the 2012 American Society of Clinical Oncology Annual Meeting.
Axitinib Shows Activity in Metastatic Renal Cell Carcinoma
Axitinib is effective in the first-line treatment of metastatic renal cell carcinoma, according to a study presented at the 2012 American Society of Clinical Oncology Annual Meeting.
Regorafenib Ups Survival in mCRC After Standard Tx Failure
Regorafenib prolongs PFS and OS in metastatic colorectal cancer that has progressed after all approved standard therapies, according to the phase 3 CORRECT trial presented at the 2012 American Society of Clinical Oncology Annual Meeting.
T-DM1 Prolongs PFS in Some HER2+ Metastatic Breast Cancer Patients
The experimental agent trastuzumab emtansine (T-DM1) offers significant and “clinically meaningful” improvement in PFS in some patients with HER2+locally advanced or metastatic breast cancer, according to a phase 3 study prestented at the 2012 American Society of Clinical Oncology Annual Meeting.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...